Daré Bioscience Stock Is Trading Higher As Bacterial Vaginosis Candidate Secures FDA Priority Review

The FDA has accepted for review Daré Bioscience Inc's (NASDAQ:DARE) marketing application for DARE-BV1 for bacterial vaginosis.
Under the priority review, the target goal date is December 7.
DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time treatment.
The application is supported by positive data from the DARE-BVFREE Phase 3 study, demonstrating 70-81% clinical cure rates from a single vaginal dose of DARE-BV1.
Price Action: DARE shares are up 7.45% at $1.73 during the market session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.

To add Benzinga News as your preferred source on Google, click here.

The FDA has accepted for review Daré Bioscience Inc's (NASDAQ:DARE) marketing application for DARE-BV1 for bacterial vaginosis.
Under the priority review, the target goal date is December 7.
DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time treatment.
The application is supported by positive data from the DARE-BVFREE Phase 3 study, demonstrating 70-81% clinical cure rates from a single vaginal dose of DARE-BV1.
Price Action: DARE shares are up 7.45% at $1.73 during the market session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.

To add Benzinga News as your preferred source on Google, click here.

ArticleFeaturedTickersList12345!!!